Skip to main content
. 2023 Jan 20;33:101430. doi: 10.1016/j.bbrep.2023.101430

Fig. 7.

Fig. 7

Proposed model to explain the action of the combined treatments. The combined treatments AZD5363+AZD8542+CCR or AZD8542+CCR+RV decrease the activation of AKT, reduce the expression of SMO, pP70S6k, pS6k, GLI1, p21 and p27, and activate the caspase-3 on U-87 MG and A172 cell lines.